Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

October Podcast: Ebola, Biosimilars, Astellas, CLL

This article was originally published in The Pink Sheet Daily

Executive Summary

Topics in the October “Pinkcast” include Ebola products, biosimilars marketing, Astellas in the U.S., and our market snapshot of chronic lymphocytic leukemia drugs.

You may also be interested in...



Ebola Treatments Could Be Orphan Candidates – But Vaccines, Probably Not

FDA expects few people would get the disease in the U.S., but many could receive a vaccine.

Astellas U.S. Priorities Are Oncology Expansion, BD – President Robinson

Astellas Pharma US expects oncology will account for 40% of sales in three years, becoming its top business segment – significant growth for a company that just four years ago had no commercial presence in oncology. The plans rely heavily on Xtandi, suggesting it might be time to ramp up business development activity.

Japan Phase III Failure To End Mono Opdivo Hopes In Ovarian Cancer?

While disappointing result will probably put an end to single-drug plans in ovarian cancer, the blockbuster anti-PD-1 immunotherapy remains in combination development for the indication.

Topics

Related Companies

UsernamePublicRestriction

Register

PS076575

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel